Dec. 22 Quick Takes: BeiGene launches incubator in Guangzhou

The BeiGene Bioisland Innovation Center, launched by BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160; Shanghai:688235), could contribute to the company’s pipeline, according to the company’s co-founder, Chairman and CEO John Oyler. Located in the Guangdong-Hong Kong-Macau Greater Bay Area, the incubator will support the research and entrepreneurship of new biotechs with infrastructure, scientific and business support.

The first patient outside of North America has received infigratinib from LianBio (NASDAQ:LIAN) after Hainan’s health commission approved the cholangiocarcinoma therapy under the Chinese province’s named patient program, part of a pilot in Hainan’s medical tourism zone. The cross-border company has rights to the FGFR inhibitor from BridgeBio Pharma Inc. (NASDAQ:BBIO) affiliate QED Therapeutics Inc...